Utilizing Diagnostics to Inform Patient Stratification and Selection in Clinical Trials
Time: 11:30 am
day: Day One
Details:
- Molecular imaging with PET/CT provides immense value for both patient selection and as a prognostic/predictive biomarker
- For PSMA theranostics, the value of FDG in addition to PSMA PET/CT will be highlighted
- It is particularly critical for phase I/II to enrich patients likely to benefit from therapy
